With more than 100 translocation partners, KMT2A rearrangement (KMT2A-r) can lead to ALL, acute myeloid leukemia (AML), and mixed phenotypic acute leukemia (MPAL), with dismal prognosis across all categories.2–5. Here, KMT2A is linked to acute lymphoblastic leukemia.